Inhibitors of the mTOR kinase are in clinical trials for the treatment of cancer; here, mutations in mTOR that can lead to drug resistance are investigated and the results are used to design a new class of mTOR inhibitors that can overcome this resistance.
- Vanessa S. Rodrik-Outmezguine
- Masanori Okaniwa
- Kevan M. Shokat